A new MRI rating scale for progressive supranuclear palsy and multiple system atrophy: validity and reliability
Identifieur interne : 001038 ( Main/Corpus ); précédent : 001037; suivant : 001039A new MRI rating scale for progressive supranuclear palsy and multiple system atrophy: validity and reliability
Auteurs : Yan Rolland ; Marc Vérin ; Christine A. Payan ; Simon Duchesne ; Eduard Kraft ; Till K. Hauser ; Josef Jarosz ; Neil Deasy ; Luc Defevbre ; Christine Delmaire ; Didier Dormont ; Albert C. Ludolph ; Gilbert Bensimon ; P Nigel LeighSource :
- Journal of Neurology, Neurosurgery & Psychiatry [ 0022-3050 ] ; 2011-09.
Abstract
Aim To evaluate a standardised MRI acquisition protocol and a new image rating scale for disease severity in patients with progressive supranuclear palsy (PSP) and multiple systems atrophy (MSA) in a large multicentre study. Methods The MRI protocol consisted of two-dimensional sagittal and axial T1, axial PD, and axial and coronal T2 weighted acquisitions. The 32 item ordinal scale evaluated abnormalities within the basal ganglia and posterior fossa, blind to diagnosis. Among 760 patients in the study population (PSP=362, MSA=398), 627 had per protocol images (PSP=297, MSA=330). Intra-rater (n=60) and inter-rater (n=555) reliability were assessed through Cohen's statistic, and scale structure through principal component analysis (PCA) (n=441). Internal consistency and reliability were checked. Discriminant and predictive validity of extracted factors and total scores were tested for disease severity as per clinical diagnosis. Results Intra-rater and inter-rater reliability were acceptable for 25 (78%) of the items scored (≥0.41). PCA revealed four meaningful clusters of covarying parameters (factor (F) F1: brainstem and cerebellum; F2: midbrain; F3: putamen; F4: other basal ganglia) with good to excellent internal consistency (Cronbach α 0.75–0.93) and moderate to excellent reliability (intraclass coefficient: F1: 0.92; F2: 0.79; F3: 0.71; F4: 0.49). The total score significantly discriminated for disease severity or diagnosis; factorial scores differentially discriminated for disease severity according to diagnosis (PSP: F1–F2; MSA: F2–F3). The total score was significantly related to survival in PSP (p<0.0007) or MSA (p<0.0005), indicating good predictive validity. Conclusions The scale is suitable for use in the context of multicentre studies and can reliably and consistently measure MRI abnormalities in PSP and MSA. Clinical Trial Registration Number The study protocol was filed in the open clinical trial registry (http://www.clinicaltrials.gov) with ID No NCT00211224.
Url:
DOI: 10.1136/jnnp.2010.214890
Links to Exploration step
ISTEX:EC1A86B2145155C772D9465608300E551C02AD9FLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>A new MRI rating scale for progressive supranuclear palsy and multiple system atrophy: validity and reliability</title><author><name sortKey="Rolland, Yan" sort="Rolland, Yan" uniqKey="Rolland Y" first="Yan" last="Rolland">Yan Rolland</name><affiliation><mods:affiliation>Medical Imaging Department, Eugène Marquis Centre, Rennes, France</mods:affiliation></affiliation></author><author><name sortKey="Verin, Marc" sort="Verin, Marc" uniqKey="Verin M" first="Marc" last="Vérin">Marc Vérin</name><affiliation><mods:affiliation>Department of Neurology, Pontchaillou University Hospital, Rennes, France</mods:affiliation></affiliation></author><author><name sortKey="Payan, Christine A" sort="Payan, Christine A" uniqKey="Payan C" first="Christine A" last="Payan">Christine A. Payan</name><affiliation><mods:affiliation>Département de Pharmacologie Clinique, Centre Hospitalo-Universitaire de la Pitié-Salpétrière, Assistance publique hôpitaux de Paris and UPMC Univ, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Duchesne, Simon" sort="Duchesne, Simon" uniqKey="Duchesne S" first="Simon" last="Duchesne">Simon Duchesne</name><affiliation><mods:affiliation>Department of Radiology and Robert Giffard Laval University Research Centre, Laval University, Quebec City, Canada</mods:affiliation></affiliation></author><author><name sortKey="Kraft, Eduard" sort="Kraft, Eduard" uniqKey="Kraft E" first="Eduard" last="Kraft">Eduard Kraft</name><affiliation><mods:affiliation>Department of Neurology, University of Ulm, Baden-Wuerttemberg, Germany</mods:affiliation></affiliation></author><author><name sortKey="Hauser, Till K" sort="Hauser, Till K" uniqKey="Hauser T" first="Till K" last="Hauser">Till K. Hauser</name><affiliation><mods:affiliation>Department of Neuroradiology, University of Tübingen, Tübingen, Germany</mods:affiliation></affiliation></author><author><name sortKey="Jarosz, Josef" sort="Jarosz, Josef" uniqKey="Jarosz J" first="Josef" last="Jarosz">Josef Jarosz</name><affiliation><mods:affiliation>Department of Neurology, Brighton and Sussex Medical School, Trafford Centre for Biomedical Research, University of Sussex Falmer, East Sussex, UK</mods:affiliation></affiliation></author><author><name sortKey="Deasy, Neil" sort="Deasy, Neil" uniqKey="Deasy N" first="Neil" last="Deasy">Neil Deasy</name><affiliation><mods:affiliation>MRC Centre for Neurodegeneration Research, King's College London, Institute of Psychiatry, Department of Clinical Neuroscience, London, UK</mods:affiliation></affiliation></author><author><name sortKey="Defevbre, Luc" sort="Defevbre, Luc" uniqKey="Defevbre L" first="Luc" last="Defevbre">Luc Defevbre</name><affiliation><mods:affiliation>Department of Neurology Movement Disorders, Lille University, Salengro Hospital, Cedex Lille, France</mods:affiliation></affiliation></author><author><name sortKey="Delmaire, Christine" sort="Delmaire, Christine" uniqKey="Delmaire C" first="Christine" last="Delmaire">Christine Delmaire</name><affiliation><mods:affiliation>Department of Neuroradiology, Lille University, Salengro Hospital, Cedex Lille, France</mods:affiliation></affiliation></author><author><name sortKey="Dormont, Didier" sort="Dormont, Didier" uniqKey="Dormont D" first="Didier" last="Dormont">Didier Dormont</name><affiliation><mods:affiliation>Département de Neuroradiologie, Hôpital de la Pitié-Salpétrière, Assistance Publique Hôpitaux de Paris and UPMC Univ, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Ludolph, Albert C" sort="Ludolph, Albert C" uniqKey="Ludolph A" first="Albert C" last="Ludolph">Albert C. Ludolph</name><affiliation><mods:affiliation>Department of Neurology, University of Ulm, Baden-Wuerttemberg, Germany</mods:affiliation></affiliation></author><author><name sortKey="Bensimon, Gilbert" sort="Bensimon, Gilbert" uniqKey="Bensimon G" first="Gilbert" last="Bensimon">Gilbert Bensimon</name><affiliation><mods:affiliation>Département de Pharmacologie Clinique, Centre Hospitalo-Universitaire de la Pitié-Salpétrière, Assistance publique hôpitaux de Paris and UPMC Univ, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Leigh, P Nigel" sort="Leigh, P Nigel" uniqKey="Leigh P" first="P Nigel" last="Leigh">P Nigel Leigh</name><affiliation><mods:affiliation>Department of Neurology, Brighton and Sussex Medical School, Trafford Centre for Biomedical Research, University of Sussex Falmer, East Sussex, UK</mods:affiliation></affiliation><affiliation><mods:affiliation>Correspondence to Professor P N Leigh, Professor of Neurology, Brighton and Sussex Medical School, Trafford Centre for Biomedical Research University of Sussex, Falmer, East Sussex BN1 9RY; bsms2899@bsms.ac.ukor Dr Gilbert Bensimon, Département de Pharmacologie Clinique, Hôpital Pitié-Salpêtrière, 47 Bd de L'Hôpital, 75651 Paris Cedex 13, France; gilbert.bensimon@psl.aphp.fr</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:EC1A86B2145155C772D9465608300E551C02AD9F</idno><date when="2011" year="2011">2011</date><idno type="doi">10.1136/jnnp.2010.214890</idno><idno type="url">https://api.istex.fr/document/EC1A86B2145155C772D9465608300E551C02AD9F/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">001038</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">A new MRI rating scale for progressive supranuclear palsy and multiple system atrophy: validity and reliability</title><author><name sortKey="Rolland, Yan" sort="Rolland, Yan" uniqKey="Rolland Y" first="Yan" last="Rolland">Yan Rolland</name><affiliation><mods:affiliation>Medical Imaging Department, Eugène Marquis Centre, Rennes, France</mods:affiliation></affiliation></author><author><name sortKey="Verin, Marc" sort="Verin, Marc" uniqKey="Verin M" first="Marc" last="Vérin">Marc Vérin</name><affiliation><mods:affiliation>Department of Neurology, Pontchaillou University Hospital, Rennes, France</mods:affiliation></affiliation></author><author><name sortKey="Payan, Christine A" sort="Payan, Christine A" uniqKey="Payan C" first="Christine A" last="Payan">Christine A. Payan</name><affiliation><mods:affiliation>Département de Pharmacologie Clinique, Centre Hospitalo-Universitaire de la Pitié-Salpétrière, Assistance publique hôpitaux de Paris and UPMC Univ, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Duchesne, Simon" sort="Duchesne, Simon" uniqKey="Duchesne S" first="Simon" last="Duchesne">Simon Duchesne</name><affiliation><mods:affiliation>Department of Radiology and Robert Giffard Laval University Research Centre, Laval University, Quebec City, Canada</mods:affiliation></affiliation></author><author><name sortKey="Kraft, Eduard" sort="Kraft, Eduard" uniqKey="Kraft E" first="Eduard" last="Kraft">Eduard Kraft</name><affiliation><mods:affiliation>Department of Neurology, University of Ulm, Baden-Wuerttemberg, Germany</mods:affiliation></affiliation></author><author><name sortKey="Hauser, Till K" sort="Hauser, Till K" uniqKey="Hauser T" first="Till K" last="Hauser">Till K. Hauser</name><affiliation><mods:affiliation>Department of Neuroradiology, University of Tübingen, Tübingen, Germany</mods:affiliation></affiliation></author><author><name sortKey="Jarosz, Josef" sort="Jarosz, Josef" uniqKey="Jarosz J" first="Josef" last="Jarosz">Josef Jarosz</name><affiliation><mods:affiliation>Department of Neurology, Brighton and Sussex Medical School, Trafford Centre for Biomedical Research, University of Sussex Falmer, East Sussex, UK</mods:affiliation></affiliation></author><author><name sortKey="Deasy, Neil" sort="Deasy, Neil" uniqKey="Deasy N" first="Neil" last="Deasy">Neil Deasy</name><affiliation><mods:affiliation>MRC Centre for Neurodegeneration Research, King's College London, Institute of Psychiatry, Department of Clinical Neuroscience, London, UK</mods:affiliation></affiliation></author><author><name sortKey="Defevbre, Luc" sort="Defevbre, Luc" uniqKey="Defevbre L" first="Luc" last="Defevbre">Luc Defevbre</name><affiliation><mods:affiliation>Department of Neurology Movement Disorders, Lille University, Salengro Hospital, Cedex Lille, France</mods:affiliation></affiliation></author><author><name sortKey="Delmaire, Christine" sort="Delmaire, Christine" uniqKey="Delmaire C" first="Christine" last="Delmaire">Christine Delmaire</name><affiliation><mods:affiliation>Department of Neuroradiology, Lille University, Salengro Hospital, Cedex Lille, France</mods:affiliation></affiliation></author><author><name sortKey="Dormont, Didier" sort="Dormont, Didier" uniqKey="Dormont D" first="Didier" last="Dormont">Didier Dormont</name><affiliation><mods:affiliation>Département de Neuroradiologie, Hôpital de la Pitié-Salpétrière, Assistance Publique Hôpitaux de Paris and UPMC Univ, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Ludolph, Albert C" sort="Ludolph, Albert C" uniqKey="Ludolph A" first="Albert C" last="Ludolph">Albert C. Ludolph</name><affiliation><mods:affiliation>Department of Neurology, University of Ulm, Baden-Wuerttemberg, Germany</mods:affiliation></affiliation></author><author><name sortKey="Bensimon, Gilbert" sort="Bensimon, Gilbert" uniqKey="Bensimon G" first="Gilbert" last="Bensimon">Gilbert Bensimon</name><affiliation><mods:affiliation>Département de Pharmacologie Clinique, Centre Hospitalo-Universitaire de la Pitié-Salpétrière, Assistance publique hôpitaux de Paris and UPMC Univ, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Leigh, P Nigel" sort="Leigh, P Nigel" uniqKey="Leigh P" first="P Nigel" last="Leigh">P Nigel Leigh</name><affiliation><mods:affiliation>Department of Neurology, Brighton and Sussex Medical School, Trafford Centre for Biomedical Research, University of Sussex Falmer, East Sussex, UK</mods:affiliation></affiliation><affiliation><mods:affiliation>Correspondence to Professor P N Leigh, Professor of Neurology, Brighton and Sussex Medical School, Trafford Centre for Biomedical Research University of Sussex, Falmer, East Sussex BN1 9RY; bsms2899@bsms.ac.ukor Dr Gilbert Bensimon, Département de Pharmacologie Clinique, Hôpital Pitié-Salpêtrière, 47 Bd de L'Hôpital, 75651 Paris Cedex 13, France; gilbert.bensimon@psl.aphp.fr</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Journal of Neurology, Neurosurgery & Psychiatry</title><title level="j" type="abbrev">J Neurol Neurosurg Psychiatry</title><idno type="ISSN">0022-3050</idno><idno type="eISSN">1468-330X</idno><imprint><publisher>BMJ Publishing Group Ltd</publisher><date type="published" when="2011-09">2011-09</date><biblScope unit="volume">82</biblScope><biblScope unit="issue">9</biblScope><biblScope unit="page" from="1025">1025</biblScope></imprint><idno type="ISSN">0022-3050</idno></series><idno type="istex">EC1A86B2145155C772D9465608300E551C02AD9F</idno><idno type="DOI">10.1136/jnnp.2010.214890</idno><idno type="href">jnnp-82-1025.pdf</idno><idno type="ArticleID">jnnp214890</idno><idno type="PMID">21386111</idno><idno type="local">jnnp;82/9/1025</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0022-3050</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract">Aim To evaluate a standardised MRI acquisition protocol and a new image rating scale for disease severity in patients with progressive supranuclear palsy (PSP) and multiple systems atrophy (MSA) in a large multicentre study. Methods The MRI protocol consisted of two-dimensional sagittal and axial T1, axial PD, and axial and coronal T2 weighted acquisitions. The 32 item ordinal scale evaluated abnormalities within the basal ganglia and posterior fossa, blind to diagnosis. Among 760 patients in the study population (PSP=362, MSA=398), 627 had per protocol images (PSP=297, MSA=330). Intra-rater (n=60) and inter-rater (n=555) reliability were assessed through Cohen's statistic, and scale structure through principal component analysis (PCA) (n=441). Internal consistency and reliability were checked. Discriminant and predictive validity of extracted factors and total scores were tested for disease severity as per clinical diagnosis. Results Intra-rater and inter-rater reliability were acceptable for 25 (78%) of the items scored (≥0.41). PCA revealed four meaningful clusters of covarying parameters (factor (F) F1: brainstem and cerebellum; F2: midbrain; F3: putamen; F4: other basal ganglia) with good to excellent internal consistency (Cronbach α 0.75–0.93) and moderate to excellent reliability (intraclass coefficient: F1: 0.92; F2: 0.79; F3: 0.71; F4: 0.49). The total score significantly discriminated for disease severity or diagnosis; factorial scores differentially discriminated for disease severity according to diagnosis (PSP: F1–F2; MSA: F2–F3). The total score was significantly related to survival in PSP (p<0.0007) or MSA (p<0.0005), indicating good predictive validity. Conclusions The scale is suitable for use in the context of multicentre studies and can reliably and consistently measure MRI abnormalities in PSP and MSA. Clinical Trial Registration Number The study protocol was filed in the open clinical trial registry (http://www.clinicaltrials.gov) with ID No NCT00211224.</div></front></TEI><istex><corpusName>bmj</corpusName><author><json:item><name>Yan Rolland</name><affiliations><json:string>Medical Imaging Department, Eugène Marquis Centre, Rennes, France</json:string></affiliations></json:item><json:item><name>Marc Vérin</name><affiliations><json:string>Department of Neurology, Pontchaillou University Hospital, Rennes, France</json:string></affiliations></json:item><json:item><name>Christine A Payan</name><affiliations><json:string>Département de Pharmacologie Clinique, Centre Hospitalo-Universitaire de la Pitié-Salpétrière, Assistance publique hôpitaux de Paris and UPMC Univ, Paris, France</json:string></affiliations></json:item><json:item><name>Simon Duchesne</name><affiliations><json:string>Department of Radiology and Robert Giffard Laval University Research Centre, Laval University, Quebec City, Canada</json:string></affiliations></json:item><json:item><name>Eduard Kraft</name><affiliations><json:string>Department of Neurology, University of Ulm, Baden-Wuerttemberg, Germany</json:string></affiliations></json:item><json:item><name>Till K Hauser</name><affiliations><json:string>Department of Neuroradiology, University of Tübingen, Tübingen, Germany</json:string></affiliations></json:item><json:item><name>Josef Jarosz</name><affiliations><json:string>Department of Neurology, Brighton and Sussex Medical School, Trafford Centre for Biomedical Research, University of Sussex Falmer, East Sussex, UK</json:string></affiliations></json:item><json:item><name>Neil Deasy</name><affiliations><json:string>MRC Centre for Neurodegeneration Research, King's College London, Institute of Psychiatry, Department of Clinical Neuroscience, London, UK</json:string></affiliations></json:item><json:item><name>Luc Defevbre</name><affiliations><json:string>Department of Neurology Movement Disorders, Lille University, Salengro Hospital, Cedex Lille, France</json:string></affiliations></json:item><json:item><name>Christine Delmaire</name><affiliations><json:string>Department of Neuroradiology, Lille University, Salengro Hospital, Cedex Lille, France</json:string></affiliations></json:item><json:item><name>Didier Dormont</name><affiliations><json:string>Département de Neuroradiologie, Hôpital de la Pitié-Salpétrière, Assistance Publique Hôpitaux de Paris and UPMC Univ, Paris, France</json:string></affiliations></json:item><json:item><name>Albert C Ludolph</name><affiliations><json:string>Department of Neurology, University of Ulm, Baden-Wuerttemberg, Germany</json:string></affiliations></json:item><json:item><name>Gilbert Bensimon</name><affiliations><json:string>Département de Pharmacologie Clinique, Centre Hospitalo-Universitaire de la Pitié-Salpétrière, Assistance publique hôpitaux de Paris and UPMC Univ, Paris, France</json:string></affiliations></json:item><json:item><name>P Nigel Leigh</name><affiliations><json:string>Department of Neurology, Brighton and Sussex Medical School, Trafford Centre for Biomedical Research, University of Sussex Falmer, East Sussex, UK</json:string><json:string>Correspondence to Professor P N Leigh, Professor of Neurology, Brighton and Sussex Medical School, Trafford Centre for Biomedical Research University of Sussex, Falmer, East Sussex BN1 9RY; bsms2899@bsms.ac.ukor Dr Gilbert Bensimon, Département de Pharmacologie Clinique, Hôpital Pitié-Salpêtrière, 47 Bd de L'Hôpital, 75651 Paris Cedex 13, France; gilbert.bensimon@psl.aphp.fr</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Research paper</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Unlocked</value></json:item></subject><language><json:string>eng</json:string></language><abstract>Aim To evaluate a standardised MRI acquisition protocol and a new image rating scale for disease severity in patients with progressive supranuclear palsy (PSP) and multiple systems atrophy (MSA) in a large multicentre study. Methods The MRI protocol consisted of two-dimensional sagittal and axial T1, axial PD, and axial and coronal T2 weighted acquisitions. The 32 item ordinal scale evaluated abnormalities within the basal ganglia and posterior fossa, blind to diagnosis. Among 760 patients in the study population (PSP=362, MSA=398), 627 had per protocol images (PSP=297, MSA=330). Intra-rater (n=60) and inter-rater (n=555) reliability were assessed through Cohen's statistic, and scale structure through principal component analysis (PCA) (n=441). Internal consistency and reliability were checked. Discriminant and predictive validity of extracted factors and total scores were tested for disease severity as per clinical diagnosis. Results Intra-rater and inter-rater reliability were acceptable for 25 (78%) of the items scored (≥0.41). PCA revealed four meaningful clusters of covarying parameters (factor (F) F1: brainstem and cerebellum; F2: midbrain; F3: putamen; F4: other basal ganglia) with good to excellent internal consistency (Cronbach α 0.75–0.93) and moderate to excellent reliability (intraclass coefficient: F1: 0.92; F2: 0.79; F3: 0.71; F4: 0.49). The total score significantly discriminated for disease severity or diagnosis; factorial scores differentially discriminated for disease severity according to diagnosis (PSP: F1–F2; MSA: F2–F3). The total score was significantly related to survival in PSP (p>0.0007) or MSA (p>0.0005), indicating good predictive validity. Conclusions The scale is suitable for use in the context of multicentre studies and can reliably and consistently measure MRI abnormalities in PSP and MSA. Clinical Trial Registration Number The study protocol was filed in the open clinical trial registry (http://www.clinicaltrials.gov) with ID No NCT00211224.</abstract><qualityIndicators><score>8.5</score><pdfVersion>1.4</pdfVersion><pdfPageSize>595.276 x 793.701 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>2</keywordCount><abstractCharCount>2008</abstractCharCount><pdfWordCount>6098</pdfWordCount><pdfCharCount>42223</pdfCharCount><pdfPageCount>8</pdfPageCount><abstractWordCount>280</abstractWordCount></qualityIndicators><title>A new MRI rating scale for progressive supranuclear palsy and multiple system atrophy: validity and reliability</title><pmid><json:string>21386111</json:string></pmid><corporate><json:item><name>on behalf of the NNIPPS Study Group</name></json:item></corporate><genre><json:string>research-article</json:string></genre><host><volume>82</volume><pages><first>1025</first></pages><issn><json:string>0022-3050</json:string></issn><issue>9</issue><genre></genre><language><json:string>unknown</json:string></language><eissn><json:string>1468-330X</json:string></eissn><title>Journal of Neurology, Neurosurgery & Psychiatry</title></host><publicationDate>2011</publicationDate><copyrightDate>2011</copyrightDate><doi><json:string>10.1136/jnnp.2010.214890</json:string></doi><id>EC1A86B2145155C772D9465608300E551C02AD9F</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/EC1A86B2145155C772D9465608300E551C02AD9F/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/EC1A86B2145155C772D9465608300E551C02AD9F/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/EC1A86B2145155C772D9465608300E551C02AD9F/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a">A new MRI rating scale for progressive supranuclear palsy and multiple system atrophy: validity and reliability</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>BMJ Publishing Group Ltd</publisher><availability><p>BMJ</p></availability><date>2011-03-08</date></publicationStmt><notesStmt><note>GB and PNL contributed equally to this paper.</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a">A new MRI rating scale for progressive supranuclear palsy and multiple system atrophy: validity and reliability</title><author><orgName>on behalf of the NNIPPS Study Group</orgName></author><author><persName><forename type="first">Yan</forename><surname>Rolland</surname></persName><affiliation>Medical Imaging Department, Eugène Marquis Centre, Rennes, France</affiliation></author><author><persName><forename type="first">Marc</forename><surname>Vérin</surname></persName><affiliation>Department of Neurology, Pontchaillou University Hospital, Rennes, France</affiliation></author><author><persName><forename type="first">Christine A</forename><surname>Payan</surname></persName><affiliation>Département de Pharmacologie Clinique, Centre Hospitalo-Universitaire de la Pitié-Salpétrière, Assistance publique hôpitaux de Paris and UPMC Univ, Paris, France</affiliation></author><author><persName><forename type="first">Simon</forename><surname>Duchesne</surname></persName><affiliation>Department of Radiology and Robert Giffard Laval University Research Centre, Laval University, Quebec City, Canada</affiliation></author><author><persName><forename type="first">Eduard</forename><surname>Kraft</surname></persName><affiliation>Department of Neurology, University of Ulm, Baden-Wuerttemberg, Germany</affiliation></author><author><persName><forename type="first">Till K</forename><surname>Hauser</surname></persName><affiliation>Department of Neuroradiology, University of Tübingen, Tübingen, Germany</affiliation></author><author><persName><forename type="first">Josef</forename><surname>Jarosz</surname></persName><affiliation>Department of Neurology, Brighton and Sussex Medical School, Trafford Centre for Biomedical Research, University of Sussex Falmer, East Sussex, UK</affiliation></author><author><persName><forename type="first">Neil</forename><surname>Deasy</surname></persName><affiliation>MRC Centre for Neurodegeneration Research, King's College London, Institute of Psychiatry, Department of Clinical Neuroscience, London, UK</affiliation></author><author><persName><forename type="first">Luc</forename><surname>Defevbre</surname></persName><affiliation>Department of Neurology Movement Disorders, Lille University, Salengro Hospital, Cedex Lille, France</affiliation></author><author><persName><forename type="first">Christine</forename><surname>Delmaire</surname></persName><affiliation>Department of Neuroradiology, Lille University, Salengro Hospital, Cedex Lille, France</affiliation></author><author><persName><forename type="first">Didier</forename><surname>Dormont</surname></persName><affiliation>Département de Neuroradiologie, Hôpital de la Pitié-Salpétrière, Assistance Publique Hôpitaux de Paris and UPMC Univ, Paris, France</affiliation></author><author><persName><forename type="first">Albert C</forename><surname>Ludolph</surname></persName><affiliation>Department of Neurology, University of Ulm, Baden-Wuerttemberg, Germany</affiliation></author><author><persName><forename type="first">Gilbert</forename><surname>Bensimon</surname></persName><affiliation>Département de Pharmacologie Clinique, Centre Hospitalo-Universitaire de la Pitié-Salpétrière, Assistance publique hôpitaux de Paris and UPMC Univ, Paris, France</affiliation></author><author><persName><forename type="first">P Nigel</forename><surname>Leigh</surname></persName><affiliation>Department of Neurology, Brighton and Sussex Medical School, Trafford Centre for Biomedical Research, University of Sussex Falmer, East Sussex, UK</affiliation><affiliation>Correspondence to Professor P N Leigh, Professor of Neurology, Brighton and Sussex Medical School, Trafford Centre for Biomedical Research University of Sussex, Falmer, East Sussex BN1 9RY; bsms2899@bsms.ac.ukor Dr Gilbert Bensimon, Département de Pharmacologie Clinique, Hôpital Pitié-Salpêtrière, 47 Bd de L'Hôpital, 75651 Paris Cedex 13, France; gilbert.bensimon@psl.aphp.fr</affiliation></author></analytic><monogr><title level="j">Journal of Neurology, Neurosurgery & Psychiatry</title><title level="j" type="abbrev">J Neurol Neurosurg Psychiatry</title><idno type="pISSN">0022-3050</idno><idno type="eISSN">1468-330X</idno><imprint><publisher>BMJ Publishing Group Ltd</publisher><date type="published" when="2011-09"></date><biblScope unit="volume">82</biblScope><biblScope unit="issue">9</biblScope><biblScope unit="page" from="1025">1025</biblScope></imprint></monogr><idno type="istex">EC1A86B2145155C772D9465608300E551C02AD9F</idno><idno type="DOI">10.1136/jnnp.2010.214890</idno><idno type="href">jnnp-82-1025.pdf</idno><idno type="ArticleID">jnnp214890</idno><idno type="PMID">21386111</idno><idno type="local">jnnp;82/9/1025</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2011-03-08</date></creation><langUsage><language ident="en">en</language></langUsage><abstract><p>Aim To evaluate a standardised MRI acquisition protocol and a new image rating scale for disease severity in patients with progressive supranuclear palsy (PSP) and multiple systems atrophy (MSA) in a large multicentre study. Methods The MRI protocol consisted of two-dimensional sagittal and axial T1, axial PD, and axial and coronal T2 weighted acquisitions. The 32 item ordinal scale evaluated abnormalities within the basal ganglia and posterior fossa, blind to diagnosis. Among 760 patients in the study population (PSP=362, MSA=398), 627 had per protocol images (PSP=297, MSA=330). Intra-rater (n=60) and inter-rater (n=555) reliability were assessed through Cohen's statistic, and scale structure through principal component analysis (PCA) (n=441). Internal consistency and reliability were checked. Discriminant and predictive validity of extracted factors and total scores were tested for disease severity as per clinical diagnosis. Results Intra-rater and inter-rater reliability were acceptable for 25 (78%) of the items scored (≥0.41). PCA revealed four meaningful clusters of covarying parameters (factor (F) F1: brainstem and cerebellum; F2: midbrain; F3: putamen; F4: other basal ganglia) with good to excellent internal consistency (Cronbach α 0.75–0.93) and moderate to excellent reliability (intraclass coefficient: F1: 0.92; F2: 0.79; F3: 0.71; F4: 0.49). The total score significantly discriminated for disease severity or diagnosis; factorial scores differentially discriminated for disease severity according to diagnosis (PSP: F1–F2; MSA: F2–F3). The total score was significantly related to survival in PSP (p<0.0007) or MSA (p<0.0005), indicating good predictive validity. Conclusions The scale is suitable for use in the context of multicentre studies and can reliably and consistently measure MRI abnormalities in PSP and MSA. Clinical Trial Registration Number The study protocol was filed in the open clinical trial registry (http://www.clinicaltrials.gov) with ID No NCT00211224.</p></abstract><textClass><keywords scheme="keyword"><list><head>hwp-journal-coll</head><item><term>Unlocked</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2011-03-08">Created</change><change when="2011-09">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/EC1A86B2145155C772D9465608300E551C02AD9F/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="corpus bmj" wicri:toSee="no header"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="no"</istex:xmlDeclaration><istex:docType PUBLIC="-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" URI="archivearticle.dtd" name="istex:docType"></istex:docType><istex:document><article article-type="research-article"><front><journal-meta><journal-id journal-id-type="hwp">jnnp</journal-id><journal-id journal-id-type="nlm-ta">J Neurol Neurosurg Psychiatry</journal-id><journal-id journal-id-type="publisher-id">jnnp</journal-id><journal-title>Journal of Neurology, Neurosurgery & Psychiatry</journal-title><abbrev-journal-title abbrev-type="publisher">J Neurol Neurosurg Psychiatry</abbrev-journal-title><abbrev-journal-title>J Neurol Neurosurg Psychiatry</abbrev-journal-title><issn pub-type="ppub">0022-3050</issn><issn pub-type="epub">1468-330X</issn><publisher><publisher-name>BMJ Publishing Group Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">jnnp214890</article-id><article-id pub-id-type="doi">10.1136/jnnp.2010.214890</article-id><article-id pub-id-type="other">jnnp;82/9/1025</article-id><article-id pub-id-type="other">jnnp;jnnp.2010.214890</article-id><article-id pub-id-type="pmid">21386111</article-id><article-id pub-id-type="other">1025</article-id><article-id pub-id-type="other">jnnp.2010.214890</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research paper</subject></subj-group><subj-group subj-group-type="hwp-journal-coll"><subject>Unlocked</subject></subj-group></article-categories><title-group><article-title>A new MRI rating scale for progressive supranuclear palsy and multiple system atrophy: validity and reliability</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Rolland</surname><given-names>Yan</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Vérin</surname><given-names>Marc</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Payan</surname><given-names>Christine A</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Duchesne</surname><given-names>Simon</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Kraft</surname><given-names>Eduard</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Hauser</surname><given-names>Till K</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Jarosz</surname><given-names>Josef</given-names></name><xref ref-type="aff" rid="aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Deasy</surname><given-names>Neil</given-names></name><xref ref-type="aff" rid="aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Defevbre</surname><given-names>Luc</given-names></name><xref ref-type="aff" rid="aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Delmaire</surname><given-names>Christine</given-names></name><xref ref-type="aff" rid="aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Dormont</surname><given-names>Didier</given-names></name><xref ref-type="aff" rid="aff11">11</xref></contrib><contrib contrib-type="author"><name><surname>Ludolph</surname><given-names>Albert C</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Bensimon</surname><given-names>Gilbert</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Leigh</surname><given-names>P Nigel</given-names></name><xref ref-type="aff" rid="aff7">7</xref></contrib><contrib contrib-type="author"><collab>on behalf of the NNIPPS Study Group</collab></contrib></contrib-group><aff id="aff1"><label>1</label>Medical Imaging Department, Eugène Marquis Centre, Rennes, France</aff><aff id="aff2"><label>2</label>Department of Neurology, Pontchaillou University Hospital, Rennes, France</aff><aff id="aff3"><label>3</label>Département de Pharmacologie Clinique, Centre Hospitalo-Universitaire de la Pitié-Salpétrière, Assistance publique hôpitaux de Paris and UPMC Univ, Paris, France</aff><aff id="aff4"><label>4</label>Department of Radiology and Robert Giffard Laval University Research Centre, Laval University, Quebec City, Canada</aff><aff id="aff5"><label>5</label>Department of Neurology, University of Ulm, Baden-Wuerttemberg, Germany</aff><aff id="aff6"><label>6</label>Department of Neuroradiology, University of Tübingen, Tübingen, Germany</aff><aff id="aff7"><label>7</label>Department of Neurology, Brighton and Sussex Medical School, Trafford Centre for Biomedical Research, University of Sussex Falmer, East Sussex, UK</aff><aff id="aff8"><label>8</label>MRC Centre for Neurodegeneration Research, King's College London, Institute of Psychiatry, Department of Clinical Neuroscience, London, UK</aff><aff id="aff9"><label>9</label>Department of Neurology Movement Disorders, Lille University, Salengro Hospital, Cedex Lille, France</aff><aff id="aff10"><label>10</label>Department of Neuroradiology, Lille University, Salengro Hospital, Cedex Lille, France</aff><aff id="aff11"><label>11</label>Département de Neuroradiologie, Hôpital de la Pitié-Salpétrière, Assistance Publique Hôpitaux de Paris and UPMC Univ, Paris, France</aff><author-notes><corresp><label>Correspondence to</label> Professor P N Leigh, Professor of Neurology, Brighton and Sussex Medical School, Trafford Centre for Biomedical Research University of Sussex, Falmer, East Sussex BN1 9RY; <email>bsms2899@bsms.ac.uk</email>or Dr Gilbert Bensimon, Département de Pharmacologie Clinique, Hôpital Pitié-Salpêtrière, 47 Bd de L'Hôpital, 75651 Paris Cedex 13, France; <email>gilbert.bensimon@psl.aphp.fr</email></corresp><fn fn-type="other"><p>GB and PNL contributed equally to this paper.</p></fn></author-notes><pub-date pub-type="epub-original"><day>8</day><month>3</month><year>2011</year></pub-date><pub-date pub-type="ppub"><month>9</month><year>2011</year></pub-date><pub-date pub-type="epub"><day>8</day><month>3</month><year>2011</year></pub-date><volume>82</volume><volume-id pub-id-type="other">82</volume-id><volume-id pub-id-type="other">82</volume-id><issue>9</issue><issue-id pub-id-type="other">jnnp;82/9</issue-id><issue-id pub-id-type="other">9</issue-id><issue-id pub-id-type="other">82/9</issue-id><fpage>1025</fpage><history><date date-type="received"><day>15</day><month>4</month><year>2010</year></date><date date-type="accepted"><day>6</day><month>1</month><year>2011</year></date></history><permissions><copyright-statement>© 2011, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.</copyright-statement><copyright-year>2011</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/2.0/">http://creativecommons.org/licenses/by-nc/2.0/</ext-link> and <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/2.0/legalcode">http://creativecommons.org/licenses/by-nc/2.0/legalcode</ext-link>.</p></license></permissions><self-uri content-type="pdf" xlink:role="full-text" xlink:href="jnnp-82-1025.pdf"></self-uri><abstract><sec><title>Aim</title><p>To evaluate a standardised MRI acquisition protocol and a new image rating scale for disease severity in patients with progressive supranuclear palsy (PSP) and multiple systems atrophy (MSA) in a large multicentre study.</p></sec><sec><title>Methods</title><p>The MRI protocol consisted of two-dimensional sagittal and axial T1, axial PD, and axial and coronal T2 weighted acquisitions. The 32 item ordinal scale evaluated abnormalities within the basal ganglia and posterior fossa, blind to diagnosis. Among 760 patients in the study population (PSP=362, MSA=398), 627 had per protocol images (PSP=297, MSA=330). Intra-rater (n=60) and inter-rater (n=555) reliability were assessed through Cohen's statistic, and scale structure through principal component analysis (PCA) (n=441). Internal consistency and reliability were checked. Discriminant and predictive validity of extracted factors and total scores were tested for disease severity as per clinical diagnosis.</p></sec><sec><title>Results</title><p>Intra-rater and inter-rater reliability were acceptable for 25 (78%) of the items scored (≥0.41). PCA revealed four meaningful clusters of covarying parameters (factor (F) F1: brainstem and cerebellum; F2: midbrain; F3: putamen; F4: other basal ganglia) with good to excellent internal consistency (Cronbach α 0.75–0.93) and moderate to excellent reliability (intraclass coefficient: F1: 0.92; F2: 0.79; F3: 0.71; F4: 0.49). The total score significantly discriminated for disease severity or diagnosis; factorial scores differentially discriminated for disease severity according to diagnosis (PSP: F1–F2; MSA: F2–F3). The total score was significantly related to survival in PSP (p<0.0007) or MSA (p<0.0005), indicating good predictive validity.</p></sec><sec><title>Conclusions</title><p>The scale is suitable for use in the context of multicentre studies and can reliably and consistently measure MRI abnormalities in PSP and MSA.</p></sec><sec><title>Clinical Trial Registration Number</title><p>The study protocol was filed in the open clinical trial registry (<ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov">http://www.clinicaltrials.gov</ext-link>) with ID No <ext-link ext-link-type="clintrialgov" xlink:href="NCT00211224">NCT00211224</ext-link>.</p></sec></abstract></article-meta></front></article></istex:document></istex:metadataXml><mods version="3.6"><titleInfo><title>A new MRI rating scale for progressive supranuclear palsy and multiple system atrophy: validity and reliability</title></titleInfo><titleInfo type="alternative" contentType="CDATA"><title>A new MRI rating scale for progressive supranuclear palsy and multiple system atrophy: validity and reliability</title></titleInfo><name type="corporate"><namePart>on behalf of the NNIPPS Study Group</namePart></name><name type="personal"><namePart type="given">Yan</namePart><namePart type="family">Rolland</namePart><affiliation>Medical Imaging Department, Eugène Marquis Centre, Rennes, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Marc</namePart><namePart type="family">Vérin</namePart><affiliation>Department of Neurology, Pontchaillou University Hospital, Rennes, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Christine A</namePart><namePart type="family">Payan</namePart><affiliation>Département de Pharmacologie Clinique, Centre Hospitalo-Universitaire de la Pitié-Salpétrière, Assistance publique hôpitaux de Paris and UPMC Univ, Paris, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Simon</namePart><namePart type="family">Duchesne</namePart><affiliation>Department of Radiology and Robert Giffard Laval University Research Centre, Laval University, Quebec City, Canada</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Eduard</namePart><namePart type="family">Kraft</namePart><affiliation>Department of Neurology, University of Ulm, Baden-Wuerttemberg, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Till K</namePart><namePart type="family">Hauser</namePart><affiliation>Department of Neuroradiology, University of Tübingen, Tübingen, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Josef</namePart><namePart type="family">Jarosz</namePart><affiliation>Department of Neurology, Brighton and Sussex Medical School, Trafford Centre for Biomedical Research, University of Sussex Falmer, East Sussex, UK</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Neil</namePart><namePart type="family">Deasy</namePart><affiliation>MRC Centre for Neurodegeneration Research, King's College London, Institute of Psychiatry, Department of Clinical Neuroscience, London, UK</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Luc</namePart><namePart type="family">Defevbre</namePart><affiliation>Department of Neurology Movement Disorders, Lille University, Salengro Hospital, Cedex Lille, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Christine</namePart><namePart type="family">Delmaire</namePart><affiliation>Department of Neuroradiology, Lille University, Salengro Hospital, Cedex Lille, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Didier</namePart><namePart type="family">Dormont</namePart><affiliation>Département de Neuroradiologie, Hôpital de la Pitié-Salpétrière, Assistance Publique Hôpitaux de Paris and UPMC Univ, Paris, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Albert C</namePart><namePart type="family">Ludolph</namePart><affiliation>Department of Neurology, University of Ulm, Baden-Wuerttemberg, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Gilbert</namePart><namePart type="family">Bensimon</namePart><affiliation>Département de Pharmacologie Clinique, Centre Hospitalo-Universitaire de la Pitié-Salpétrière, Assistance publique hôpitaux de Paris and UPMC Univ, Paris, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P Nigel</namePart><namePart type="family">Leigh</namePart><affiliation>Department of Neurology, Brighton and Sussex Medical School, Trafford Centre for Biomedical Research, University of Sussex Falmer, East Sussex, UK</affiliation><affiliation>Correspondence to Professor P N Leigh, Professor of Neurology, Brighton and Sussex Medical School, Trafford Centre for Biomedical Research University of Sussex, Falmer, East Sussex BN1 9RY; bsms2899@bsms.ac.ukor Dr Gilbert Bensimon, Département de Pharmacologie Clinique, Hôpital Pitié-Salpêtrière, 47 Bd de L'Hôpital, 75651 Paris Cedex 13, France; gilbert.bensimon@psl.aphp.fr</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="research-article" displayLabel="research-article"></genre><subject><genre>hwp-journal-coll</genre><topic>Unlocked</topic></subject><originInfo><publisher>BMJ Publishing Group Ltd</publisher><dateIssued encoding="w3cdtf">2011-09</dateIssued><dateCreated encoding="w3cdtf">2011-03-08</dateCreated><copyrightDate encoding="w3cdtf">2011</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm><languageTerm type="code" authority="rfc3066">en</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType></physicalDescription><abstract>Aim To evaluate a standardised MRI acquisition protocol and a new image rating scale for disease severity in patients with progressive supranuclear palsy (PSP) and multiple systems atrophy (MSA) in a large multicentre study. Methods The MRI protocol consisted of two-dimensional sagittal and axial T1, axial PD, and axial and coronal T2 weighted acquisitions. The 32 item ordinal scale evaluated abnormalities within the basal ganglia and posterior fossa, blind to diagnosis. Among 760 patients in the study population (PSP=362, MSA=398), 627 had per protocol images (PSP=297, MSA=330). Intra-rater (n=60) and inter-rater (n=555) reliability were assessed through Cohen's statistic, and scale structure through principal component analysis (PCA) (n=441). Internal consistency and reliability were checked. Discriminant and predictive validity of extracted factors and total scores were tested for disease severity as per clinical diagnosis. Results Intra-rater and inter-rater reliability were acceptable for 25 (78%) of the items scored (≥0.41). PCA revealed four meaningful clusters of covarying parameters (factor (F) F1: brainstem and cerebellum; F2: midbrain; F3: putamen; F4: other basal ganglia) with good to excellent internal consistency (Cronbach α 0.75–0.93) and moderate to excellent reliability (intraclass coefficient: F1: 0.92; F2: 0.79; F3: 0.71; F4: 0.49). The total score significantly discriminated for disease severity or diagnosis; factorial scores differentially discriminated for disease severity according to diagnosis (PSP: F1–F2; MSA: F2–F3). The total score was significantly related to survival in PSP (p<0.0007) or MSA (p<0.0005), indicating good predictive validity. Conclusions The scale is suitable for use in the context of multicentre studies and can reliably and consistently measure MRI abnormalities in PSP and MSA. Clinical Trial Registration Number The study protocol was filed in the open clinical trial registry (http://www.clinicaltrials.gov) with ID No NCT00211224.</abstract><note type="footnotes">GB and PNL contributed equally to this paper.</note><relatedItem type="host"><titleInfo><title>Journal of Neurology, Neurosurgery & Psychiatry</title></titleInfo><titleInfo type="abbreviated"><title>J Neurol Neurosurg Psychiatry</title></titleInfo><genre type="Journal">journal</genre><identifier type="ISSN">0022-3050</identifier><identifier type="eISSN">1468-330X</identifier><identifier type="PublisherID">jnnp</identifier><identifier type="PublisherID-hwp">jnnp</identifier><identifier type="PublisherID-nlm-ta">J Neurol Neurosurg Psychiatry</identifier><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>82</number></detail><detail type="issue"><caption>no.</caption><number>9</number></detail><extent unit="pages"><start>1025</start></extent></part></relatedItem><identifier type="istex">EC1A86B2145155C772D9465608300E551C02AD9F</identifier><identifier type="DOI">10.1136/jnnp.2010.214890</identifier><identifier type="href">jnnp-82-1025.pdf</identifier><identifier type="ArticleID">jnnp214890</identifier><identifier type="PMID">21386111</identifier><identifier type="local">jnnp;82/9/1025</identifier><accessCondition type="use and reproduction" contentType="open-access">This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/2.0/ and http://creativecommons.org/licenses/by-nc/2.0/legalcode.</accessCondition><recordInfo><recordContentSource>BMJ</recordContentSource></recordInfo></mods></metadata><annexes><json:item><original>true</original><mimetype>image/jpeg</mimetype><extension>jpeg</extension><uri>https://api.istex.fr/document/EC1A86B2145155C772D9465608300E551C02AD9F/annexes/jpeg</uri></json:item></annexes><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001038 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001038 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:EC1A86B2145155C772D9465608300E551C02AD9F
|texte= A new MRI rating scale for progressive supranuclear palsy and multiple system atrophy: validity and reliability
}}
| This area was generated with Dilib version V0.6.23. |  |